beyond spring pharma stock

BeyondSpring is a noticeably small company with a market capitalisation of US392m. Ad Direxion Daily PharmaMedical 3X Bull ETFs.

Beyondspring Announces Fourth Quarter And Year End 2021 Financial Results And Provides A Corporate Update

New target price is 462 above last closing price of US243.

. The Closing Price Days High Days Low and Days Volume have been adjusted to account for any stock splits andor dividends. Ramon Mohanlal MD PhD. In China we own a 5797 interest in our.

Headquartered in New York City we are committed to raising the standard of care for cancer patients with first-in-class treatments that improve lives and clinical outcomes for. Joining us on todays call is Dr. Investors are justifiably excited about the partners new agreement to commercialize and co-develop BeyondSprings neutropenia-prevention candidate called.

Real time BeyondSpring Inc. Events presentations. Ad Dont miss out on opportunities open an account in 10 minutes.

Lan Huang Beyond Springs co-founder chairman and chief executive officer. Learn More About Our Differentiated RD Strategy. Is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies.

According to the issued ratings of 6 analysts in the last year the consensus rating for BeyondSpring stock is Hold based on the current 1 sell rating 3 hold ratings and 2 buy. Most companies this size are not always actively traded. Shares of BeyondSpring BYSI 372 soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung.

Shares of BeyondSpring NASDAQ. Pharmaceuticals Stocks Drug Approvals. BYSI Q4 2021 Earnings Call Transcript.

The service offers end-to-end research on both investing and trading ideas everyday and includes a 150-stock watchlist and two 40-stock model portfolios that are. BYSI now has a market cap of 132mn a cash reserve of 93mn a small debt of 45mn and a large short interest of 23. Up from US1175 the current price target is an average from 4 analysts.

BYSI stock price quote stock graph news analysis. Companies this small are. Stock news by MarketWatch.

Processa Pharmaceuticals has a consensus price target of. Global pharmaceutical company BeyondSpring announced positive findings in a late-stage trial of a drug combo to treat second- and third-line nonsmall cell lung cancer. EDT on Friday following the drugmakers.

1 We own global rights to plinabulin in all countries except China. Ad Horizon Is A Leading High-Growth Biopharma Company. Find real-time BYSI - Beyondspring Inc stock quotes company profile news and forecasts from CNN Business.

Their forecasts range from 500 to 6500. It had slid 27 in the six months through Tuesday. Lan Huang Beyond Springs co-founder chairman and chief executive officer.

Discover our most recent and upcoming events as well as download informative presentationsall right here. Ad Dont miss out on opportunities open an account in 10 minutes. BYSI Complete BeyondSpring Inc.

They recently received or are about to receive 30mn. BeyondSpring is a global clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from. Shares of BeyondSpring BYSI -160 -- a clinical-stage biopharmaceutical company -- are down by 181 as of 1126 am.

The stock recently traded at 2711 compared with its Tuesday close at 963. BYSI stock are taking off on Wednesday following an important update regarding the firms lung cancer treatment. On average they anticipate BeyondSprings share price to reach 3000 in the next twelve months.

View real-time stock prices and stock quotes for a full financial overview. Ad Horizon Is A Leading High-Growth Biopharma Company. Learn More About Our Differentiated RD Strategy.

Price target increased to US1367.

Plinabulin Dublin 3 Bpi 2358 103 Beyondspring